Spots Global Cancer Trial Database for Changes in DNA After Radiation Therapy in Patients With Prostate Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Changes in DNA After Radiation Therapy in Patients With Prostate Cancer
Official Title: Investigating Markers of Radiation Outcome in Patients With Intermediate-Risk Prostate Cancer Using DNA Microarray Analysis: An RTOG Pilot Study
Study ID: NCT00899912
Conditions
Study Description
Brief Summary: RATIONALE: Collecting and storing samples of tissue from patients with cancer to study in the laboratory may help doctors learn more about changes that may occur in DNA after radiation therapy and identify biomarkers related to cancer. PURPOSE: This laboratory study is looking at changes in DNA after radiation therapy in patients with prostate cancer.
Detailed Description: OBJECTIVES: Primary * Demonstrate the feasibility of acquiring specimens, both frozen and paraffin-embedded, to yield RNA of adequate quality to perform DNA microarray studies on markers of radiotherapy outcome in patients with intermediate-risk prostate cancer. Secondary * Compare the gene expression results from frozen tissue and paraffin-embedded tissue to see the correlation between the 2 methods in patients treated on the brachytherapy alone arm of protocol RTOG-0232. * Find genes that are expressed differentially before and after radiation therapy in patients treated on the brachytherapy plus external-beam radiation therapy arm of protocol RTOG-0232. * Find gene expression patterns in patients treated on either arm of protocol RTOG-0232 who have significant associations with biochemically as well as clinically apparent local and distant failure. OUTLINE: This is a multicenter, pilot study. Frozen and paraffin-embedded tissue samples are studied for biomarker/laboratory analysis. DNA microarray analysis is performed on the samples to assess markers of radiotherapy outcome. PROJECTED ACCRUAL: A total of 156 patients will be accrued for this study.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: MALE
Healthy Volunteers: No
Locations
Georgia Cancer Center for Excellence at Grady Memorial Hospital, Atlanta, Georgia, United States
Emory Crawford Long Hospital, Atlanta, Georgia, United States
Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
Cancer Institute at St. John's Hospital, Springfield, Illinois, United States
Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis, Saint Louis, Missouri, United States
Barnes-Jewish West County Hospital, Saint Louis, Missouri, United States
Siteman Cancer Center at Barnes-Jewish St. Peters Hospital - St. Peters, Saint Peters, Missouri, United States
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
MedCentral - Mansfield Hospital, Mansfield, Ohio, United States
Fox Chase Cancer Center - Philadelphia, Philadelphia, Pennsylvania, United States
Contact Details
Name: Arnab Chakravarti, MD
Affiliation: Ohio State University
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
